3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
2
Neoplasms
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
8
pembrolizumab
6
Filgrastim
5
Busulfan
5
fludarabine phosphate
4
fludarabine
4
Nivolumab
4
Flow Cytometry
4
Antilymphocyte Serum
4
Alemtuzumab
4
Tacrolimus
3
Stem Cell Transplantation
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Mycophenolic Acid
3
Melphalan
3
Dexamethasone
3
Carboplatin
3
Biopsy
3
Azacitidine
3
valspodar
2
atezolizumab
2
aldesleukin
2
X-Rays
2
Vorinostat
2
Vincristine
2
Thiotepa
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Genistein
×
Genitourinary
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts